Literature DB >> 6832812

Humoral immune response in chinchillas to the capsular polysaccharides of Streptococcus pneumoniae.

G S Giebink, G Schiffman.   

Abstract

Vaccines made from the capsular polysaccharides of Streptococcus pneumoniae have been shown to reduce the incidence of pneumococcal disease in certain populations and have recently been evaluated for their ability to elicit protection against experimental pneumococcal otitis media in a chinchilla model. In this study, chinchillas were vaccinated with a dodecavalent preparation of pneumococcal capsular polysaccharides (PCP) to obtain more information on the immunogenicity of these polysaccharide antigens. All 12 PCP types elicited an antibody response, but the optimum PCP dose and the kinetics of the antibody response varied among types. Immunological paralysis was demonstrated with an immunogenic dose of PCP after primary immunization with a large PCP dose (25 micrograms or more). Pertussis vaccine acted as neither an immunoadjuvant nor an immunosuppressant in the serum antibody response to type 7F PCP in chinchillas.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6832812      PMCID: PMC347999          DOI: 10.1128/iai.39.2.638-644.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Kinetics of the antibody response to type III pneumococcal polysaccharide. II. Factors influencing the serum antibody levels after immunization with an optimally immunogenic dose of antigen.

Authors:  J M Jones; D F Amsbaugh; B Prescott
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

2.  The effect of Bordetella pertussis on the antibody response in mice to type III pneumococcal polysaccharide.

Authors:  A S Kong; S I Morse
Journal:  J Immunol       Date:  1976-04       Impact factor: 5.422

3.  Kinetics of the antibody response to type III pneumococcal polysaccharide (SSS-III). I. Use of 125I-labeled SSS-III to study serum antibody levels, as well as the distribution and excretion of antigen after immunization.

Authors:  J M Jones; D F Amsbaugh; B Prescott
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

4.  Immunological paralysis of mice with pneumococcal polysaccharide antigens.

Authors:  W J Halliday
Journal:  Bacteriol Rev       Date:  1971-09

5.  Studies on immunological paralysis. 3. Recirculation and antibody-neutralizing activity of 14C-labelled type 3 pneumococcal polysaccharide in paralysed mice.

Authors:  J G Howard; G H Christie; M J Jacob; J Elson
Journal:  Clin Exp Immunol       Date:  1970-10       Impact factor: 4.330

6.  Regulation of the antibody response to pneumococcal polysaccharide by thymus-derived cells.

Authors:  P J Baker; D F Amsbaugh; P W Stashak; G Caldes; B Prescott
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

7.  Efficacy of pneumococcal polysaccharide vaccine in preventing acute otitis media in infants in Huntsville, Alabama.

Authors:  J L Sloyer; J H Ploussard; V M Howie
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

8.  Graphical method for evaluating antibody response to vaccines.

Authors:  G R Siber; B J Ransil; G Schiffman
Journal:  Infect Immun       Date:  1980-05       Impact factor: 3.441

9.  Modification of otitis media following vaccination with the capsular polysaccharide of Streptococcus pneumoniae in chinchillas.

Authors:  G S Giebink; G Schiffman; K Petty; P G Quie
Journal:  J Infect Dis       Date:  1978-10       Impact factor: 5.226

10.  Modification of antibody response to type III pneumopolysaccharide by route of injection of pertussis vaccine.

Authors:  R S Speirs; R W Benson; D W Roberts
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

View more
  1 in total

1.  Enzyme immunoassay for detection of immunoglobulin G (IgG), IgM, and IgA antibodies against type 6B pneumococcal capsular polysaccharide and cell wall C polysaccharide in chinchilla serum.

Authors:  M Koskela; M Harris; G S Giebink
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.